CN110501449B - 一种坎地沙坦酯基因毒性杂质的检测方法 - Google Patents
一种坎地沙坦酯基因毒性杂质的检测方法 Download PDFInfo
- Publication number
- CN110501449B CN110501449B CN201910681603.5A CN201910681603A CN110501449B CN 110501449 B CN110501449 B CN 110501449B CN 201910681603 A CN201910681603 A CN 201910681603A CN 110501449 B CN110501449 B CN 110501449B
- Authority
- CN
- China
- Prior art keywords
- candesartan cilexetil
- derivative
- solution
- acetonitrile
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical group C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 239000012535 impurity Substances 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 50
- 231100000331 toxic Toxicity 0.000 title claims abstract description 15
- 230000002588 toxic effect Effects 0.000 title claims abstract description 15
- 229960004349 candesartan cilexetil Drugs 0.000 claims abstract description 75
- 238000006243 chemical reaction Methods 0.000 claims abstract description 55
- ONZWFHWHTYZZLM-UHFFFAOYSA-N 1-chloroethyl cyclohexyl carbonate Chemical compound CC(Cl)OC(=O)OC1CCCCC1 ONZWFHWHTYZZLM-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 238000001212 derivatisation Methods 0.000 claims abstract description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 207
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 69
- 239000000243 solution Substances 0.000 claims description 67
- 239000013558 reference substance Substances 0.000 claims description 51
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 44
- 239000000523 sample Substances 0.000 claims description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 238000005303 weighing Methods 0.000 claims description 28
- 238000001514 detection method Methods 0.000 claims description 25
- 238000007865 diluting Methods 0.000 claims description 25
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 22
- 238000010828 elution Methods 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 20
- 239000012085 test solution Substances 0.000 claims description 20
- 239000011550 stock solution Substances 0.000 claims description 19
- 239000012488 sample solution Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 14
- 239000012088 reference solution Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 238000010812 external standard method Methods 0.000 claims description 5
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- 231100000024 genotoxic Toxicity 0.000 abstract description 15
- 230000001738 genotoxic effect Effects 0.000 abstract description 15
- 238000004458 analytical method Methods 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 8
- 238000003908 quality control method Methods 0.000 abstract description 2
- 239000012071 phase Substances 0.000 description 36
- 238000005406 washing Methods 0.000 description 19
- 238000001914 filtration Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 238000003756 stirring Methods 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 238000011084 recovery Methods 0.000 description 11
- 239000003643 water by type Substances 0.000 description 9
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 8
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 8
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 8
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical group CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012490 blank solution Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- -1 1-chlorohexyl carbonate Chemical compound 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- UPXWDSOAEHGDBH-UHFFFAOYSA-N OC(=O)OC1(Cl)CCCCC1 Chemical compound OC(=O)OC1(Cl)CCCCC1 UPXWDSOAEHGDBH-UHFFFAOYSA-N 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/047—Standards external
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910681603.5A CN110501449B (zh) | 2019-07-26 | 2019-07-26 | 一种坎地沙坦酯基因毒性杂质的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910681603.5A CN110501449B (zh) | 2019-07-26 | 2019-07-26 | 一种坎地沙坦酯基因毒性杂质的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110501449A CN110501449A (zh) | 2019-11-26 |
CN110501449B true CN110501449B (zh) | 2021-08-13 |
Family
ID=68587083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910681603.5A Active CN110501449B (zh) | 2019-07-26 | 2019-07-26 | 一种坎地沙坦酯基因毒性杂质的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110501449B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111458444B (zh) * | 2020-05-14 | 2022-06-21 | 广东省药品检验所(广东省药品质量研究所、广东省口岸药品检验所) | 一种测定坎地沙坦酯中杂质的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1896455A2 (en) * | 2005-06-06 | 2008-03-12 | Medichem, S.A. | Process for the preparation of tetrazolyl compounds |
SI22340A (sl) * | 2006-07-28 | 2008-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopki za pripravo amorfnih in kristalnih oblikkandesartan cileksetila |
CN101936961B (zh) * | 2009-07-01 | 2013-04-17 | 浙江华海药业股份有限公司 | 一种坎地沙坦酯的高效液相色谱分析法 |
CN102670604B (zh) * | 2012-05-18 | 2014-11-19 | 四川升和药业股份有限公司 | 含有坎地沙坦、氨氯地平的组合物及其制备、检验方法和用途 |
CN103396406B (zh) * | 2013-08-07 | 2014-07-23 | 迪沙药业集团有限公司 | 一种坎地沙坦酯的制备方法 |
WO2015090635A1 (en) * | 2013-12-20 | 2015-06-25 | Farma Grs, D.O.O. | A new process for the preparation of candesartan cilexetil |
CN105153124B (zh) * | 2015-08-26 | 2018-03-16 | 山西皇城相府药业有限公司 | 一种坎地沙坦酯的制备方法 |
CN109305965B (zh) * | 2017-07-28 | 2021-03-16 | 武汉朗来科技发展有限公司 | 苯并咪唑衍生物制备及分析方法 |
-
2019
- 2019-07-26 CN CN201910681603.5A patent/CN110501449B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110501449A (zh) | 2019-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104655751B (zh) | 一种检测达泊西汀中有机溶剂残留的方法 | |
CN107037153B (zh) | 高效液相色谱法检测al58805原料药或药物制剂中基因毒性杂质的方法 | |
CN106896166B (zh) | 一种琥珀酸曲格列汀原料及其制剂中有关物质的分析方法 | |
CN106841443A (zh) | 一种测定左卡尼汀注射液含量及杂质的方法及其用途 | |
CN110455944A (zh) | 一种同时检测长春西汀中阿朴长春胺酸与长春胺酸的方法 | |
CN105017243B (zh) | 一种头孢曲松钠光降解产物及其制备方法和分析检测方法 | |
CN110501449B (zh) | 一种坎地沙坦酯基因毒性杂质的检测方法 | |
CN109682900B (zh) | 采用高效液相色谱法测定神经酸含量的方法 | |
CN108008024A (zh) | 多索茶碱原料药中基因毒性杂质的检测方法 | |
CN112014510B (zh) | 一种hplc法测定马来酸桂哌齐特中间体中氯乙酸残留检测方法 | |
CN106338564B (zh) | 一种用于检测维格列汀中间体中对映异构体的方法 | |
CN109799298B (zh) | 一种吡仑帕奈原料药中有关物质的检测方法 | |
CN106841415A (zh) | 一种阿齐沙坦原料及其制剂中有关物质的分析方法 | |
CN114689737B (zh) | 一种s-邻氯苯甘氨酸甲酯酒石酸盐有关物质的分析方法 | |
CN110596269B (zh) | 一种同时检测肌酸粉中多种成分的含量测定方法 | |
CN106153756B (zh) | 一种检测依维莫司中雷帕霉素的高效液相色谱法 | |
CN114518413A (zh) | 一种卡托普利原料药中脯氨酸的含量测定方法 | |
CN105651900A (zh) | 分离测定丁酸氯倍他松及其制剂中工艺杂质的方法 | |
CN113030328A (zh) | 一种检测盐酸伊伐布雷定中基因毒性杂质的方法 | |
CN113030323A (zh) | 一种尼洛替尼原料药中残留溶剂的检测方法 | |
CN113740476A (zh) | 布瓦西坦药物中杂质l-2-氨基丁酰胺盐酸盐含量的检测方法 | |
CN113466360B (zh) | 一种阿齐沙坦6种有关物质检测方法 | |
CN109781894A (zh) | 一种利非司特r异构体的检测方法 | |
CN114942278B (zh) | 来特莫韦中间体二d-(+)-二对甲基苯甲酰酒石酸乙酸乙酯络合物有关物质的分析方法 | |
CN116930368B (zh) | 一种司替戊醇异构体的检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210707 Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Applicant after: Dijia Pharmaceutical Group Co.,Ltd. Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 266440 No.268, Tianrun Road, Wendeng economic and Technological Development Zone, Weihai City, Shandong Province Applicant before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Effective date of registration: 20210707 Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Applicant after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Applicant before: Dijia Pharmaceutical Group Co.,Ltd. Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A detection method for genotoxic impurities of candesartan axetil Effective date of registration: 20211108 Granted publication date: 20210813 Pledgee: Bank of China Limited Weihai Branch Pledgor: Dijia Pharmaceutical Group Co.,Ltd. Registration number: Y2021980012081 |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: 264205 268 Tianrun Road, Wendeng economic and Technological Development Zone, Weihai, Shandong Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230801 Granted publication date: 20210813 Pledgee: Bank of China Limited Weihai Branch Pledgor: Dijia Pharmaceutical Group Co.,Ltd. Registration number: Y2021980012081 |